Search - tctmd.com

Displaying 1 - 20 of 51

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

Vasospasm Linked to Higher Atherosclerotic Risk in Patients With ANOCA

Yael L. Maxwell

January 27, 2022

News Daily News

OMT Boosts Survival in Revascularized Patients at 10 Years

Michael O'Riordan

June 29, 2021

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Shelley Wood

January 14, 2020

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Evolocumab Gains Expanded Indication for Primary Prevention

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Vasospasm Linked to Higher Atherosclerotic Risk in Patients With ANOCA

OMT Boosts Survival in Revascularized Patients at 10 Years

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

FDA Approves Icosapent Ethyl for Reducing CVD Events

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Recurrent Events Common Among Young Patients With CAD

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content